DEINOVE: DNV3837 Antibiotic Candidate: the Phase II Clinical Trial to Treat Continues in the USA
DEINOVE: DNV3837 Antibiotic Candidate: the Phase II Clinical Trial to Treat Continues in the USA
DEINOVE is a French biotech company that uses its lead generation platform to develop innovative anti-infective drugs, is pursuing the Phase II clinical trial of its antibiotic candidate DNV3837, in a context where U.S. hospitals are still fighting the COVID-19 pandemic. The Company thanks the clinicians for their commitment to this trial, as they face an unprecedented health crisis.
DNV3837…
View On WordPress












